Takhzyro (lanadelumab-flyo) is a biologic medicine used to prevent hereditary angioedema (HAE) attacks in people who are 2 years or older. During an HAE attack, swelling under the skin happens in ...

Even if you’re doing everything you can to avoid an episode of hereditary angioedema (HAE) — dodging injuries, preventing respiratory illnesses, taking medication — it’s not always possible to ward ...

After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the European ...

The EC’s approval was based on results from the phase 3 OASIS-HAE study. The study showed that an 80mg dose of Dawnzera every ...

The goal of acute treatment of an hereditary angioedema (HAE) attack is to reduce its duration and severity and thus limit its impact on the patient’s functional ability and prevent a potentially ...

The U.S. Food and Drug Administration (FDA) on Friday approved BioCryst Pharmaceuticals Inc.’s (NASDAQ: BCRX) New Drug Application (NDA) for the use of an oral pellet formulation of once-daily ...

The European Commission has approved Otsuka's Dawnzera for the prevention of recurrent attacks in rare disease hereditary angioedema (HAE), a drug that can be self-administered by patients with weeks ...

Despite the availability of long-term prophylaxis (LTP), a substantial proportion of patients with hereditary angioedema (HAE) in Sweden continue to require repeated on-demand or short-term treatments ...

RESEARCH TRIANGLE PARK, N.C., Dec. 12, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (BCRX) (Nasdaq: BCRX) today announced that the U.S. Food and Drug Administration (FDA) has approved its ...

Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly faster versus placebo (p<0.0001) All secondary efficacy endpoints met (p<0.0001), including End of ...